Global viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the upcoming global viral vector manufacturing market trends expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.
Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6890
However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.
Segmentation:
The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.
The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.
The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.
The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.
The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.
The market, by application, has been segmented into gene therapy and vaccinology.
The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players:
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global viral vector manufacturing market owing to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.
Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment